Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044759 · ClinicalTrials.gov registry record · Phase 3
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
A Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00044759: Completed Phase 3 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00044759 is a Phase 3 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044759, a Phase 3 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
Interventions
- DRUG Piperacillin/Tazobactam (Tazocin)
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
What the finished NCT00044759 record still lists
NCT00044759 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Piperacillin/Tazobactam (Tazocin) is the first listed.
NCT00044759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00044759 about?
NCT00044759 is a clinical study titled "Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma". To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
What is the current status of trial NCT00044759?
This trial is currently completed. It is a Phase 3 study. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00044759?
The interventions under investigation include: Piperacillin/Tazobactam (Tazocin) (DRUG).
Who is sponsoring clinical trial NCT00044759?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.